Gene therapy shot aims to tame autoimmune diseases in early trial

NCT ID NCT07339540

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to check safety, but researchers will also measure how well it controls symptoms. About 45 adults aged 18 to 65 are being enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis idiopathic inflammatory myopathy Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease myositis disease Recurrence systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR REFRACTORY ANCA ASSOCIATED VASCULITIS RECURRENT OR REFRACTORY IDIOPATHIC INFLAMMATORY MYOPATHY RECURRENT OR REFRACTORY IGG4 RELATED DISEASES RECURRENT OR REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS RECURRENT OR REFRACTORY SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.